Literature DB >> 17302899

Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjögren's syndrome.

M P Spachidou1, E Bourazopoulou, C I Maratheftis, E K Kapsogeorgou, H M Moutsopoulos, A G Tzioufas, M N Manoussakis.   

Abstract

Toll-like receptors (TLR) play an essential role in the activation of both innate and adaptive immune responses. Salivary gland epithelial cells (SGEC) may participate in the development of glandular inflammatory reactions that characterize primary Sjögren's syndrome (pSS). In this study we sought to assess the expression and function of several TLR molecules in cultured non-neoplastic SGEC obtained from pSS patients and disease controls. Long-term cultured non-neoplastic SGEC derived from pSS patients (SS-SGEC) and disease controls (control-SGEC), as well as the monocytic cell line THP-1 (positive control cell line), were examined by reverse transcription-polymerase chain reaction (RT-PCR) analysis and quantitative real-time PCR for mRNA expression of TLR1, -2, -3 and -4 molecules. TLR function was assessed by the induction of the expression (flow cytometry) of the immunoregulatory molecules CD54/intercellular adhesion molecule-1 (ICAM-1), CD40, CD86/B7 x 2, major histocompatibility complex (MHC) class I and MHC class II following treatment with the TLR ligands: Staphylococcus aureus peptidoglycan (TLR2), the synthetic dsRNA analogue polyinosinic:cytidylic acid (TLR3) and Escherichia coli lipopolysaccharide (TLR4). SGEC were found to express functional TLR2, -3 and -4 molecules, as attested by dose-dependent up-regulation of surface ICAM-1, CD40 and MHC-I expression (as well as of reciprocal TLR mRNA) following treatment with the respective TLR-ligands. SS-SGEC lines displayed significantly higher constitutive expression of TLR1 (P=0 x 0027), TLR2 (P=0 x 01) and TLR4 (P=0 x 03) mRNA compared to control-SGEC. This study demonstrates that cultured SGEC express functional TLR molecules; the high constitutive TLR expression by SS-SGEC is probably suggestive of the intrinsic activation of epithelial cells in pSS and further supports the role of this type of tissue in pathogenesis of the disorder.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17302899      PMCID: PMC1810489          DOI: 10.1111/j.1365-2249.2006.03311.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Response of human pulmonary epithelial cells to lipopolysaccharide involves Toll-like receptor 4 (TLR4)-dependent signaling pathways: evidence for an intracellular compartmentalization of TLR4.

Authors:  Loïc Guillot; Samir Medjane; Karine Le-Barillec; Viviane Balloy; Claire Danel; Michel Chignard; Mustapha Si-Tahar
Journal:  J Biol Chem       Date:  2003-11-04       Impact factor: 5.157

Review 2.  Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?

Authors:  Evangelos Andreakos; Brian Foxwell; Marc Feldmann
Journal:  Immunol Rev       Date:  2004-12       Impact factor: 12.988

Review 3.  Sjögren's syndrome: autoimmune epithelitis.

Authors:  H M Moutsopoulos
Journal:  Clin Immunol Immunopathol       Date:  1994-08

4.  Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes.

Authors:  F X Zhang; C J Kirschning; R Mancinelli; X P Xu; Y Jin; E Faure; A Mantovani; M Rothe; M Muzio; M Arditi
Journal:  J Biol Chem       Date:  1999-03-19       Impact factor: 5.157

5.  Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjögren's syndrome.

Authors:  M N Manoussakis; I D Dimitriou; E K Kapsogeorgou; G Xanthou; S Paikos; M Polihronis; H M Moutsopoulos
Journal:  Arthritis Rheum       Date:  1999-02

6.  Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus.

Authors:  Loïc Guillot; Ronan Le Goffic; Sarah Bloch; Nicolas Escriou; Shizuo Akira; Michel Chignard; Mustapha Si-Tahar
Journal:  J Biol Chem       Date:  2004-12-03       Impact factor: 5.157

7.  Activation of Toll-like receptor 2 on human tracheobronchial epithelial cells induces the antimicrobial peptide human beta defensin-2.

Authors:  Cheryl J Hertz; Qi Wu; Edith Martin Porter; Yan J Zhang; Karl-Heinz Weismüller; Paul J Godowski; Tomas Ganz; Scott H Randell; Robert L Modlin
Journal:  J Immunol       Date:  2003-12-15       Impact factor: 5.422

8.  A novel and effective approach of developing aggressive experimental autoimmune gastritis in neonatal thymectomized BALB/c mouse by polyinosinic:polycytidylic acid.

Authors:  Y Kobayashi; H Murakami; S M F Akbar; H Matsui; M Onji
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

9.  Utility of the housekeeping genes 18S rRNA, beta-actin and glyceraldehyde-3-phosphate-dehydrogenase for normalization in real-time quantitative reverse transcriptase-polymerase chain reaction analysis of gene expression in human T lymphocytes.

Authors:  A Bas; G Forsberg; S Hammarström; M-L Hammarström
Journal:  Scand J Immunol       Date:  2004-06       Impact factor: 3.487

10.  Reactive oxygen and nitrogen species differentially regulate Toll-like receptor 4-mediated activation of NF-kappa B and interleukin-8 expression.

Authors:  Kieran A Ryan; Michael F Smith; Michael K Sanders; Peter B Ernst
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

View more
  69 in total

Review 1.  Toll-like receptors in ocular surface disease.

Authors:  Rachel L Redfern; Alison M McDermott
Journal:  Exp Eye Res       Date:  2010-03-24       Impact factor: 3.467

Review 2.  TLR-4 Signaling vs. Immune Checkpoints, miRNAs Molecules, Cancer Stem Cells, and Wingless-Signaling Interplay in Glioblastoma Multiforme-Future Perspectives.

Authors:  Jakub Litak; Cezary Grochowski; Joanna Litak; Ida Osuchowska; Krzysztof Gosik; Elżbieta Radzikowska; Piotr Kamieniak; Jacek Rolinski
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

3.  Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis.

Authors:  Gikas E Katsifis; Sofia Rekka; Niki M Moutsopoulos; Stanley Pillemer; Sharon M Wahl
Journal:  Am J Pathol       Date:  2009-08-21       Impact factor: 4.307

4.  Upregulation of the TLR3 pathway by Kaposi's sarcoma-associated herpesvirus during primary infection.

Authors:  John West; Blossom Damania
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

Review 5.  Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases.

Authors:  Jing Li; Xiaohui Wang; Fengchun Zhang; Hang Yin
Journal:  Pharmacol Ther       Date:  2013-03-24       Impact factor: 12.310

Review 6.  Update on Pathogenesis of Sjogren's Syndrome.

Authors:  Pulukool Sandhya; Biji Theyilamannil Kurien; Debashish Danda; Robert Hal Scofield
Journal:  Curr Rheumatol Rev       Date:  2017

Review 7.  Treatment of primary Sjögren syndrome.

Authors:  Alain Saraux; Jacques-Olivier Pers; Valérie Devauchelle-Pensec
Journal:  Nat Rev Rheumatol       Date:  2016-07-14       Impact factor: 20.543

8.  Cutting Edge: Commensal Microbiota Has Disparate Effects on Manifestations of Polyglandular Autoimmune Inflammation.

Authors:  Camilla H F Hansen; Leonid A Yurkovetskiy; Alexander V Chervonsky
Journal:  J Immunol       Date:  2016-06-20       Impact factor: 5.422

Review 9.  TLR2 and TLR4 in autoimmune diseases: a comprehensive review.

Authors:  Yu Liu; Heng Yin; Ming Zhao; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

10.  Toll-like receptor 3 stimulation promotes Ro52/TRIM21 synthesis and nuclear redistribution in salivary gland epithelial cells, partially via type I interferon pathway.

Authors:  N C Kyriakidis; E K Kapsogeorgou; V C Gourzi; O D Konsta; G E Baltatzis; A G Tzioufas
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.